This latter can be related to the AML genetic background as a recent study showed that the proportion of proliferating LSC increased within AML samples with core-binding factor (CBF) mutations and sensitive to chemotherapy as opposed to poor prognosis samples carrying FLT3-ITD mutation and normal karyotype. This evidence concerns the gene CEBPZ and acute myeloid leukemia.